archivestock

Low-angle view of a logo on a facade at the headquarters of Nektar Therapeutics, a biopharmaceutical ... More company located on 3rd Street, in the Mission Bay District of San Francisco, California, October 29, 2018. (Photo by Smith Collection/Gado/Getty Images)Getty Images Nektar Therapeutics (NASDAQ: NKTR) stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin for treating moderate-to-severe atopic dermatitis (eczema), marking a pivotal moment for the cash-strapped biotech company. The study met both primary and secondary...

CANADA - 2025/02/12: In this photo illustration, the SoFi Technologies, Inc. logo is seen displayed ... More on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images SoFi stock (NASDAQ: SOFI) has seen a significant increase of over 15% in the past month. This surge appears to be partly fueled by the successful IPO of Chime, which seems to have had a positive ripple effect across the broader fintech sector. After a multi-year freeze in public offerings, fintech companies like Chime are finally...

Jennifer Saibil  |  The Motley FoolTop business leaders see recession risk fadingCEOs of nearly 280 U.S. companies say the odds of a downturn in the second half of 2025 are shrinking, many shifting to growth expectations.Straight Arrow NewsThe S&P 500 is at nearly 6,000 and only 3% off of its all-time highs. While many investors are excited about the prospect of the market hitting new highs, some investors might be wondering how high it can go.It's a question that investors have grappled with many times, and yet the market has...

INDIA - 2025/06/08: In this photo illustration, a Gilead Sciences logo is seen displayed on a ... More smartphone and in the background. (Photo Illustration by Avishek Das/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images Despite a recent setback with an FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P 500’s modest 2% gain. The company is actively collaborating with authorities...

Brick facade of Amazon office building with logo, San Francisco, California, May 27, 2025. (Photo by ... More Smith Collection/Gado/Getty Images)Gado via Getty Images Over the last year, Amazon stock (NASDAQ: AMZN) has appreciated 16%, closely mirroring the NASDAQ’s 14% increase. This year has been rather tumultuous for Amazon stock. After reaching peaks above $240 in January, the stock decreased by over 30% to just below $170 by April. This drop was mainly influenced by President Trump’s vigorous trade policies. Yet, as trade tensions subdued, the stock rebounded 30% from...

Things have been good for stocks over the last two months. Maybe too good, according to a new report from Bank of America.Since its most recent low on April 8, the S&P 500 and Vanguard's Total World Stock Index are up 20% as investors have piled into the market at a near-record pace. On an annualized basis, 2025 has seen the second-highest inflows into global stocks ever, trailing only 2024, BofA's Chief Investment Strategist Michael Hartnett said in a client note Friday. For US stocks, it's the third-highest year ever,...

CANADA - 2025/05/29: In this photo illustration, the GameStop (Game Stop) logo is seen displayed on ... More a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images Meme stock – GameStop (NYSE:GME) – is set to release its earnings on Tuesday, June 10, 2025. Historically, GameStop's stock has exhibited a favorable one-day return in 55% of cases following earnings announcements over the last five years. The average positive return has been 10.2%, with the highest one-day gain reaching 35.2%. For traders focused on...

Tenaya Therapeutics, Inc. SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s chief Executive Officer, will participate in several upcoming investment conferences. Details are as follows: Morgan Stanley 22nd Annual Global Healthcare Conference Date: Thursday, September 5, 2024 Format: Fireside chat 10th Annual World Medical Innovation ForumDate: Monday, September 23, 2024Format: Panel discussion Chardan’s 8th...

LONDON,ENGLAND - MAY 30: A photo illustration of a Mounjaro pen on May 30 2025 in London, England. ... More Mounjaro is a treatment for weight loss and type 2 diabetes. (Photo by Peter Dazeley via Getty Images)Peter Dazeley Question: Why would you pay 81 times earnings for AbbVie stock when you can buy LLY for a similar valuation of 76 times earnings? You wouldn’t, especially when you consider three simple facts: Growth: Eli Lilly's growth rate is accelerating at over 30%, dwarfing AbbVie's under 5%. Over the last three...

CHONGQING, CHINA - OCTOBER 31: The Regeneron webpage is displayed on a smartphone in front of the ... More Regeneron Pharmaceuticals, Inc. logo on October 31, 2024 in Chongqing, China. (Photo by Cheng Xin/Getty Images)Getty Images Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD) treatment in conjunction with Sanofi, during a late-stage clinical trial. One of the two trials did not achieve its primary endpoint, which is a significant setback...